消化系统肿瘤“免疫治疗前移”的探索

Exploration of“immunotherapy moving forward”for digestive system tumors

免疫检查点抑制剂的出现为肿瘤治疗带来了新的曙光。免疫检查点抑制剂需要激活自身免疫对抗肿瘤细胞,因此,在患者免疫状态更好时使用免疫治疗可能会为患者带来更多获益。目前免疫治疗多用于肿瘤的后线治疗,但经过多线治疗的患者一般状态较差,免疫治疗的效果可能降低。“免疫治疗前移”指在肿瘤治疗的过程中前线应用免疫治疗,以期达到更好的治疗效果。本文就消化系统肿瘤中“免疫治疗前移”的背景、临床试验及待解决问题进行综述。

The emergence of immunosuppressive checkpoint inhibitors has brought new hope for tumor treatment.Immune checkpoint inhibitors need to activate autoimmune anti-tumor cells,so immunotherapy may bring more benefits to patients when their immune status is better.At present,immunotherapy is mostly used for the posterior line treatment of tumor,but the patients after multi-line treatment are generally in poor condition,and the effect of immunotherapy may be reduced.“Immunotherapy forward”refers to the application of immunotherapy in the process of tumor treatment in order to achieve better therapeutic effects.This article reviews the background,clinical trials and problems to be solved of“immunotherapy forward”in digestive system tumors.